search button
Open Access

A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma

  • Authors:
    • Jing Guo
    • Zhuang Wang
    • Yazhou Miao
    • Yutao Shen
    • Mingxuan Li
    • Lei Gong
    • Hongyun Wang
    • Yue He
    • Hua Gao
    • Qian Liu
    • Chuzhong Li
    • Yazhuo Zhang

  • View Affiliations

  • Published online on: November 2, 2018     https://doi.org/10.3892/or.2018.6851
  • Pages: 113-124

  • Copyright : © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical non‑functioning pituitary adenoma (NFPA) accounts for >30% of all pituitary adenomas, and the recurrence rate is notably high. The ability to predict tumour recurrence during initial surgery will aid in determining if adjunctive therapy is required to reduce recurrence. With the aim of developing a circular RNA (circRNA) signature to improve prognosis prediction in NFPA, the present study examined the circRNA expression profiles in 73 patients with NFPA from Beijing Tiantan Hospital using high‑throughput RNA chip technology. The dataset was randomly separated into a training group and a test group using an R program. In the training group (n=37), a Cox proportional hazards regression model was used to analyse the genes associated with the recurrence and progression‑free survival (PFS) of patients with NFPA. Meanwhile, a random survival forest algorithm, Kaplan‑Meier and receiver operating characteristic curve (ROC) analyses were used to determine the multi‑circRNA signature with the largest area under the ROC curve (AUROC) and verify its efficacy in the test group (n=36). In the training and test groups, the signatures of two circRNAs (hsa_circ_0000066 and hsa_circ_0069707) were specifically associated with the PFS of patients with NFPA (log‑rank P<0.05). Furthermore, the two‑circRNA signature had a high prediction accuracy for tumour recurrence, with an AUROC of 0.87 and 0.67 in the training and test groups, respectively; and the discriminative power of the signature was greater compared with that of age. The present study is the first to suggest a circRNA signature with a clinical application value for predicting recurrence/progression in patients with NFPA.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 41 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Guo J, Wang Z, Miao Y, Shen Y, Li M, Gong L, Wang H, He Y, Gao H, Liu Q, Liu Q, et al: A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncol Rep 41: 113-124, 2019
APA
Guo, J., Wang, Z., Miao, Y., Shen, Y., Li, M., Gong, L. ... Zhang, Y. (2019). A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncology Reports, 41, 113-124. https://doi.org/10.3892/or.2018.6851
MLA
Guo, J., Wang, Z., Miao, Y., Shen, Y., Li, M., Gong, L., Wang, H., He, Y., Gao, H., Liu, Q., Li, C., Zhang, Y."A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma". Oncology Reports 41.1 (2019): 113-124.
Chicago
Guo, J., Wang, Z., Miao, Y., Shen, Y., Li, M., Gong, L., Wang, H., He, Y., Gao, H., Liu, Q., Li, C., Zhang, Y."A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma". Oncology Reports 41, no. 1 (2019): 113-124. https://doi.org/10.3892/or.2018.6851